Nasofan Aqueous (Fluticasone Propionate)

Fluticasone propionate is a synthetic glucocorticoid that binds to intracellular glucocorticoid receptors. The drug‑receptor complex then moves into the cell nucleus where it alters gene transcription, suppressing the release of inflammatory cytokines and mediators. This results in decreased vascular permeability, reduced edema, and overall relief of nasal inflammation.

The specific dosing regimen for Nasofan Aqueous is determined by the prescribing healthcare professional based on the patient’s age, severity of symptoms, and response to therapy. Typical regimens involve one or two sprays per nostril once daily, but the exact number of sprays and frequency should follow the prescriber’s instructions.

Safety data for fluticasone propionate in pregnancy and lactation are limited. It should only be used if the potential benefit justifies any possible risk to the fetus or infant. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss the use of Nasofan Aqueous with their healthcare provider.

To request Nasofan Aqueous, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide. After the enquiry, the sales team will verify trade or institutional credentials, then provide pricing, availability, shipping details (including any cold‑chain requirements) and assist with import documentation.

Nasofan Aqueous (fluticasone propionate) is comparable to other intranasal corticosteroids such as mometasone furoate or beclomethasone dipropionate in terms of anti‑inflammatory potency. Fluticasone has a high receptor affinity and low systemic bioavailability, which may translate to a favorable safety profile. Choice of agent often depends on patient preference, device type, and individual response.

Nasofan Aqueous should be stored at room temperature, below 25 °C (77 °F). Keep the bottle in its original packaging, protect it from moisture and direct sunlight, and ensure the cap is tightly closed when not in use. Do not freeze the product, and discard any spray that appears discolored or has been used beyond the recommended period after opening.

Before the first use, prime the spray by pressing the actuator several times until a fine mist is visible. Gently blow the nose, tilt the head slightly forward, and insert the nozzle into one nostril while closing the other nostril with a finger. Press the actuator to deliver the prescribed number of sprays, then repeat in the opposite nostril if required. Avoid inhaling deeply during administration.

Serious but rare risks include nasal septal perforation, adrenal suppression with prolonged high‑dose use, cataracts or glaucoma, and severe allergic reactions such as anaphylaxis. Patients should be instructed to seek immediate medical attention if they experience persistent nosebleeds, visual changes, severe headache, or signs of systemic corticosteroid effects.

Nasofan Aqueous should be avoided in individuals with a known hypersensitivity to fluticasone propionate, other corticosteroids, or any component of the formulation. It is also contraindicated in patients with active untreated fungal, bacterial, or viral infections of the nasal passages, and in those who have recently undergone nasal surgery or trauma without medical guidance.